VERIMATRIX Announces the Initiation of Coverage of Its Stock by Portzamparc
Regulatory News:
VERIMATRIX(Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today is pleased to announce the initiation of coverage by Portzamparc.
Portzamparc initiates the coverage of VERIMATRIX with a study entitled: «Towards recurring and protected income », giving a BUY recommendation and a Target Price of € 0.55, compared to a closing price of € 0.45 on May 31, 2024.
The research will be available on the VERIMATRIX website: https://investors.verimatrix.com/
VERIMATRIX will also participate to the MID & SMALL CAPS conference organized by Portzamparc, on June 11, 2024.
This coverage will improve the stock market visibility and enrich the consensus of financial analysts, with ODDO BHF, which already covers the stock.
Upcoming events:
Shareholders’ Meeting: 13 June
Publication of H2 2024 revenue and results: 25 July 2024 (after market)
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit https://www.verimatrix.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603978420/en/
Contact information
Verimatrix Investors Contacts:
Jean-François Labadie
Chief Financial Officer
finance@verimatrix.com
SEITOSEI.ACTIFIN
Mathilde Guillemot-Costes
mathilde.guillemot@seitosei-actifin.com
Verimatrix Media Contacts:
USA
Matthew Zintel, Zintel
Public Relations
matthew.zintel@zintelpr.com
Financial press
SEITOSEI.ACTIFIN
Michael Scholze
Michael.scholze@seitosei-actifin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThinkPalm and RAD Join Forces to Deliver a Smart Business IoT Solution, Offering CSPs a Competitive Edge17.9.2025 10:00:00 EEST | Press release
ThinkPalm and RAD have partnered to integrate NetvirE, ThinkPalm’s advanced IIoT platform, and RAD’s Smart Business IoT solution to enable smarter industrial operations. This collaboration gives Communication Service Providers (CSPs) a competitive edge in digital transformation, remote asset management, and IoT services. 360°, End-to-End IoT Offering The Smart Business IoT solution combines advanced IoT gateways, smart sensors, and intelligent dashboards into one integrated system. It delivers real-time, historical, and AI-driven insights for remote monitoring, predictive maintenance, and activity detection, enabling CSPs to move beyond SIM-based plans and offer high-value, integrated solutions for smarter asset decisions without requiring IT expertise. Expanding CSP Horizons in the UK and Europe For CSPs in competitive markets like the UK and Europe, ThinkPalm’s expertise combined with RAD's industry leadership offers an unparalleled advantage. Together, they deliver secure, tailored
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 09:57:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting new data across its broad portfolio of dermatological treatments including new real-world data of lebrikizumab on atopic dermatitis, new clinical data of tildrakizumab on psoriasis and tirbanibulin on actinic keratosis. The 34th EADV congress will take place from September 17 to 20 in Paris, France. At the congress, Almirall contributes a total of 44 scientific abstracts focused on advancing patient care across the company’s broad portfolio of dermatological treatments including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa. With a strong emphasis on real-world evidence, patient-reported outcomes, and well-being, Almirall’s scientific programme includes multiple presentations, two expert-led symposia on psoriasis and atopic dermatitis, and an interactive exh
SES delivered unprecedented MEO satellite connectivity for French Navy’s Clemenceau 25 mission17.9.2025 09:50:00 EEST | Press release
SES announced today that the French Navy’s aircraft carrier Charles de Gaulle leveraged its secure and reliable O3b mPOWER satcom service – Managed Naval mPOWERED – during the Clemenceau 25 mission. This high-throughput, low-latency Medium Earth Orbit (MEO) connectivity solution supported all of the aircraft carrier’s operations, while facilitating collaboration with mission partners. During the five-month deployment, the French Carrier Strike Group (GAN) covered 40,000 nautical miles and conducted various exercises and joint activities with around twenty allied nations. The connectivity provided by SES ensured optimal performance and uninterrupted operational availability for the aircraft carrier’s mission-critical applications. Thanks to the global reach, reliability and exceptional high-speed capacity of the Managed Naval mPOWERED solution, which can deliver several hundred Mb/s of guaranteed throughput, the Charles de Gaulle aircraft carrier enjoyed continuous connectivity througho
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 09:00:00 EEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 08:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support the planned regulatory submissions for povorcitinib in HS in Europe and the United States in 2025 and early 2026, respectively. The presentation will take place today at 2:45 p.m. CEST during a late-breaking oral presentation (Session: Late Breaking News; Presentation ID D1T01.1C) at the European Association of Dermatology and Venereology (EADV) 2025 Congress. “HS remains a challenging and often debilitating condition and many patients are in need of new, well-tolerated and effective therapies that address prominent signs and symptoms of the disease, including inflammatory lesions and pain,” said Pablo J. Cagnoni, M.D., President and Head of Res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom